Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2545560 | 1.00 | MAPT (0.43) | MAPTKDM4ERAB9AL3MBTL1BRAF | |
| SCHEMBL757901 | 0.83 | KMT2A (0.51) | MAPTKDM4ERAB9AL3MBTL1EPHX2 | |
| SCHEMBL3719051 | 0.82 | MAPT (0.37) | MAPTRAB9AL3MBTL1EPHX2GAA | |
| SCHEMBL3719954 | 0.81 | MAPT (0.36) | MAPTRAB9AL3MBTL1EPHX2GAA | |
| SCHEMBL17133931 | 0.80 | MAPT (0.43) | MAPTKDM4ERAB9AGAASMN1; SMN2 | |
| SCHEMBL17146174 | 0.80 | MAPT (0.43) | MAPTKDM4ERAB9AGAASMN1; SMN2 | |
| SCHEMBL17133930 | 0.80 | MAPT (0.43) | MAPTKDM4ERAB9AGAASMN1; SMN2 | |
| SCHEMBL3649917 | 0.80 | PARP10 (0.58) | MAPTKDM4ERAB9AL3MBTL1EPHX2 | |
| SCHEMBL2786289 | 0.78 | AR (0.53) | MAPTKDM4ERAB9AL3MBTL1MAPK1 | |
| SCHEMBL8116738 | 0.76 | L3MBTL1 (0.47) | MAPTKDM4ERAB9AL3MBTL1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2188254-B1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | MAPT 3258/4885KDM4E 4017/4885RAB9A 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.